



**NCI-FREDERICK
INSTITUTIONAL BIOSAFETY COMMITTEE**

Minutes
July 15, 2008
NCI-Frederick

The NCI-Frederick Institutional Biosafety Committee was convened at 12:05 p.m. in the Building 549 Executive Boardroom with the following members in attendance:

Ms. Theresa Bell, Secretary	
Dr. Randall Morin, Chair	Dr. Dan McVicar
Dr. Serguei Kozlov	Dr. Michael Baseler
Dr. David Derse	Dr. David Garfinkel
Mr. Lucien Winegar	Ms. Dianna Boissey
Mr. Scott Jendrek	Ms. Alberta Peugeot
Dr. Bruce Crise	Dr. Stephen Hughes

Members not in attendance: Dr. Henry Hearn, Dr. Melinda Hollingshead, Dr. Eric Freed, Dr. Stephen Creekmore

Others in attendance: Dr. Scott Keimig, Ms. Cara Leitch, Dr. Robert Thomas

Dr. Morin called the meeting to order. The June 2008 minutes will be distributed for review in the next week.

NEW BUSINESS

08-45 (Virador/Kohn) "Propagation and Characterization of BAG3 Transgenic Mice"

- One of the lead reviewers still needs to review the responses to the IBC questions.
- Carcinogen questions are addressed in the Animal Study Proposal by the ACUC.
- The PI must address what is in the MMTV promoter? It is possible to get packaging and mobilization by endogenous MMTV when combined with the

MMTV promoter, which may provide the complete collection of replicative genes for MMTV.

- The hazards of possible mobilization with MMTV must be acknowledged.

Dr. McVicar made a motion to conditionally approve pending resolution of the above items, Dr. Kozlov seconded, and all were in favor.

AMENDMENTS

07-09 (Wolff) “Myeloid Proliferation and Myelodysplastic Disease Susceptibility of Knock-out and Transgenic Mice”

- A MIG retrovirus is being proposed to induce myeloid leukemia in mice.
- The original registration was approved for work with ecotropic virus, now they are proposing to use amphotropic virus. More importantly, the material is also oncogenic. The original paperwork is lacking sufficient detail to address the potential hazards and mitigation measures to perform this work safely.
- How the material will be transported from Bethesda to Frederick must be addressed.
- Who will be performing the injections with the amphotropic virus into genetically modified animals, and how will these injections be done safely to protect the workers?
- The oncogene derivative is replication defective but may not remain so when inserted into animals potentially harboring endogenous viruses.
- PI must address the potential of the mouse to shed virus, how the mice will be housed, and how the bedding and caging will be changed to protect animal handlers.
- There should be an informed consent to verify that all those working with these animals and materials have been adequately informed of the hazards and understand the risks and mitigation measures.
- Identification of what will be done with both replication competent and replication incompetent virus is needed.
- A laboratory specific Standard Operating Procedure or protocol is necessary to address the safety issues.

Dr. McVicar made a motion to defer approval pending resolution of the above issues and further review by IBC lead reviewers, Dr. Crise seconded, and all were in favor.

OUTSTANDING ITEMS

07-70 (Trinchieri) “Toxoplasma Gondii and the Innate Response”

- Responses have been received from the PI and sent to a lead reviewer; however, some questions remain.

- The collaborator providing the material states it is "clean". The registering PI must provide the IBC with the reassurance that the material is clean. It has been stated that the mouse feces will not harbor any *T. gondii*, but are the hazards still similar, and how should animal housing and cage changing be addressed to accommodate the potential hazards.
- The lead reviewer is continuing to review the protocol.

OTHER BUSINESS

- The Bloodborne Pathogen Program is 96% compliant. The new training portal for new on-line training was launched today, July 15, 2008 and is ready for use.

- OHS reported a non-human primate injury to two NHP workers located in Bethesda. The employees were transferring a rhesus monkey from the home cage to a transport cage. The transfer was made using a pole and collar technique on which they both had received prior training. The monkey turned around in the cage, and in an attempt to readjust the monkey, one of the technicians was scratched. The other technician reacted and pulled his arms back scratching his hand on a chair. They both proceeded to scrub their wounds and reported to OMS. The supervisor will verify retraining on these procedures and will also enroll the individuals in the Train-the-trainer course for NHPs.

- Dr. Serguei Kozlov discussed the up and coming work with fluorescence based imaging. A modification request sent through the ACUC was also forwarded to the IBC for review. Although the fluorescence based imaging does not fall within the purview of the IBC's review parameters, Dr. Kozlov thought this was a good time to introduce the emerging technology to the committee for familiarity.

-The IBC also discussed the misleading information posted on some vendor websites regarding the safety features of various research materials they market. Essentially some vendor(s) are marketing the envelope as the primary safety feature; however, if a lab contains multiple materials with different envelope deletions, the lab must ensure that there are no overlapping regions present in the lab at the same time. These issues will be addressed per IBC registration on a case-by-case basis.

The meeting ended at 1:00 p.m.

Theresa D. Bell, MPH, CBSP
IBC Secretary

Ms. Cara Leitch
IBC Coordinator

Biological Safety Officer, EHS

Sr. Safety Specialist, EHS

APPROVED:

Randall S. Morin, Dr. P.H.
Chairman, NCI-Frederick IBC
Director, EHS

Date

xc: Dr. Reynolds
Mr. Wheatley
Dr. Arthur
Mr. Butfer